PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Evonetix commences access programme for synthesised DNA

Researchers are invited to apply to receive DNA that has been synthesised using Evonetix’s platform.

Evonetix has announced the opening of its early access programme for semiconductor synthesised DNA. The company’s DNA synthesis capability brings together patented semiconductor chip design and thermally controlled synthesis chemistry, which will be integral to the company’s future gene synthesis platforms.

Evonetix’s proprietary process uses a novel silicon chip to control the synthesis of DNA at many thousands of independent thermally controlled reaction sites on the chip surface. This approach enables the accurate synthesis of thousands of sequences on a single chip to meet the demand for complex libraries and assembly of long DNA, addressing the DNA supply bottleneck in the field of synthetic biology.

Researchers are also invited to apply to be included in the company’s early access programme to receive some of the first DNA prepared using its technology and demonstrate the efficacy of Evonetix DNA in routine molecular biology workflows. The company will then look to scale up the parallel synthesis capacity of its semiconductor chips as it works toward future full commercialisation of its technology.

Matt Hayes, founder and chief technology officer at Evonetix, explained: “We have been working on optimising the different elements of our technology ready to share DNA with researchers. Reaching this point in our development is a key milestone, paving the way for the expansion in scale that only semiconductor-based technologies can achieve.”

Colin McCracken, chief executive officer of Evonetix, added: “Biology is driving a revolution that will change the way we live and help solve some of the biggest problems faced by our planet today. At the core of this is the ability to deliver DNA better and faster to researchers working on these global challenges. The current model for DNA synthesis can’t deliver on the future demand for DNA. Building a platform capable of this requires highly parallel, distributed synthesis.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026